Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

29.62 +0.62 (+2.14%)

Delayed Quote Updated: 12:47 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

61 62 Next >

Gapping stocks in Monday's session ↗

March 09, 2026

Via Chartmill

The Pivot to Legitimacy: Hims & Hers Health (HIMS) Faces a New Era of Personalized Medicine

March 09, 2026

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most...

Via Finterra

Topics Artificial Intelligence Economy

Wondering what's happening in today's pre-market session? ↗

March 09, 2026

Via Chartmill

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗

March 09, 2026

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Via Stocktwits

Topics Intellectual Property Lawsuit

Hims & Hers Announces Strategic Shift for US Weight Loss Business

March 09, 2026

From Hims & Hers

Via Business Wire

Oil Shock Sends Nasdaq, S&P 500 Futures Lower: Why USO, INDO, HIMS, NVDA Are On Traders' Radar Today ↗

March 09, 2026

Data from Stocktwits showed that retail sentiment on SPY and QQQ remains ‘bearish.’

Via Stocktwits

Topics ETFs Economy Government

HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗

March 09, 2026

Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs.

Via Stocktwits

Topics Intellectual Property Lawsuit

Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗

March 07, 2026

According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.

Via Stocktwits

Topics Initial Public Offering Intellectual Property Lawsuit

Tariffs News & Market Chaos ↗

March 06, 2026

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

Via The Motley Fool

Topics Economy Government World Trade

HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown ↗

March 06, 2026

The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories.

Via Stocktwits

Topics Earnings Lawsuit

The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes

March 04, 2026

NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗

March 04, 2026

The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro.

Via Stocktwits

Topics Lawsuit

Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances ↗

March 03, 2026

The Futurum Group CEO Daniel Newman said Hims is the “most likely public company play” for peptides at scale.

Via Stocktwits

Topics Earnings Supply Chain

What's Behind The Jump In Hims & Hers Health Stock? ↗

March 02, 2026

Shares of Hims & Hers Health, Inc. (NASDAQ: HIMS) are rising Monday after Secretary of Health and Human Services Robert F. Kennedy Jr. said on the Joe Rogan podcast that several peptide compounds, a...

Via Benzinga

Unexpected Stock Picks and Looking to the Future ↗

March 02, 2026

Why does the shortest month of the year sometimes feel like the longest?

Via The Motley Fool

Why I'm Not Worried About Novo Nordisk Stock ↗

March 02, 2026

The stock is down big of late, but the business is by no means doomed.

Via The Motley Fool

Topics Intellectual Property

Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

March 02, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

MarketBeat Week in Review – 02/23 - 02/27 ↗

February 28, 2026

Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets...

Via MarketBeat

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key...

Via StockStory

Topics Economy Government Stocks

Law Offices of Howard G. Smith Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

February 27, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? ↗

February 27, 2026

The company is looking toward international markets to boost its growth.

Via The Motley Fool

Topics Intellectual Property Lawsuit

Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗

February 27, 2026

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.

Via The Motley Fool

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Via The Motley Fool

The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

February 25, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

HIMS Stock Plummets After Wall Street Downgrade, Price Target Cuts Following 'Disappointing' Q4 Report ↗

February 24, 2026

HIMS stock is currently trading at levels last seen in September 2024 and has fallen over 50% year-to-date.

Via Stocktwits

Topics Artificial Intelligence

Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation

February 24, 2026

As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4...

Via Finterra

Topics Earnings Economy Initial Public Offering

Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗

February 24, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

HIMS Stock Slumps Nearly 10% After-Hours: How CEO Dudum Plans To Offset GLP-1 Risk ↗

February 23, 2026

The company reiterated its longer-term targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.

Via Stocktwits

Topics Earnings

Hims & Hers (HIMS) Earnings Call Transcript ↗

February 23, 2026

Hims & Hers (HIMS) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.